Chronic Diseases

Showing 15 posts of 18 posts found.

How will biomarker-led diagnostics reshape respiratory medicine?

October 11, 2026
Asthma & COPD, COPD, Chronic Diseases, Diagnostics, biomarkers, clinical trial

By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed through symptoms, lung function and …

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study

October 11, 2026
Chronic Diseases, NHS, Oncology, cardiovascular disease, survey

People in their forties account for almost three-quarters of those who do not attend NHS Health Checks, highlighting the challenge …

EpiEndo publishes new data supporting glasmacinal’s potential in COPD

June 13, 2025
Medical Communications, Research and Development Chronic Diseases, EpiEndo Pharmaceuticals, Fraunhofer Institute for Toxicology and Experimental Medicine, antimicrobial resistance, chronic obstructive pulmonary disease (COPD), lung disease

EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of …

Digital platform for hypertension management launches in Europe

June 13, 2025
Business Services, Technical Consultancy Chronic Diseases, HealthTech, Newel Health, digital platform, high blood pressure, hypertension management, hypertension therapy

Newel Health, a European healthtech company specialising in digital medical devices, has announced that Amicomed, its digital platform for hypertension …

GRI Bio announces two global patents granted for Europe and Japan

April 2, 2025
Research and Development Chronic Diseases, GRI Bio, autoimmune diseases, biotech, fibrotic diseases, inflammatory diseases, patent

GRI Bio, a biotech company that specialises in treatment for inflammatory, fibrotic and autoimmune diseases, has announced that two global …

Dupixent approved as first biologic medicine in Japan for COPD patients

April 2, 2025
Research and Development COPD, Chronic Diseases, Regeneron, Sanofi, biotech, respiratory disease

The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …

lungs

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

May 7, 2024
Research and Development Chiesi, Chronic Diseases, Gossamer Bio, PAH, PH-ILD, collaboration

US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …

Vertex announces positive results from trial for cystic fibrosis combination treatment

February 6, 2024
Research and Development Chronic Diseases, Vertex pharmaceuticals, clinical trial, combination treatment, cystic fibrosis

Vertex Pharmaceuticals has announced positive results from its once-daily vanzacaftor/tezacaftor/deutivacaftor programme, the company’s phase 3 programme for the treatment of …

C4X receives $11m milestone payment from AstraZeneca

January 3, 2024
Sales and Marketing AstraZeneca, C4X, C4X Discovery, Chronic Diseases

C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca which has been triggered …

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023
Research and Development Arcturus Therapeutics, Chronic Diseases, FDA, ODD, cystic fibrosis

Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …

glsun-mall-9xmv81sz5fw-unsplash

Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark

November 10, 2023
Manufacturing and Production Chronic Diseases, Denmark, Novo Nordisk, investment, manufacturing

Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, …

First patient dosed in phase 1 study for chronic hepatitis B treatment

August 31, 2023
Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B

ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …

The Gateway to Local Adoption Series

Latest content